FDA cleared IND application to enable phase II trial of ViralClear’s merimepodib to treat adult patients with advanced COVID-19 to proceed
| | | | |

FDA cleared IND application to enable phase II trial of ViralClear’s merimepodib to treat adult patients with advanced COVID-19 to proceed

On May 18, 2020, BioSig Technologies and its subsidiary, ViralClear Pharmaceuticals, announced the U.S. Food and Drug Administration…